Latest Strategy Changes News

Lakes Blue Energy reported a $1.5 million quarterly operational spend and completed the $6.5 million sale of its 49% interest in PEP 169, while progressing drilling approvals for the Wombat-5 well in Victoria.

Torque Metals delivers standout drilling results at its Paris Gold Project, confirming high-grade gold zones beyond existing resources, while bolstering its portfolio with new gold and lithium tenements and a successful $1M share placement.

AUCyber has received a new acquisition proposal from Interactive Pty Ltd but maintains its recommendation for shareholders to accept 5GN’s revised and unconditional offer.

Emerald Resources NL has reported record quarterly gold production at its Okvau Gold Mine, alongside significant resource expansions in Cambodia and Australia, positioning the company for robust growth.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Gas2Grid navigates regulatory headwinds in Australia by pursuing new petroleum ventures in the Philippines while contesting a significant legal claim in France. The company’s ASX suspension persists as it seeks to restore compliance through fresh contracts.

Beonic's Q2 FY2025 results reveal steady recurring revenue growth and a significant gross margin improvement, underpinning its path to cashflow breakeven. Strategic contract wins and leadership appointments position the company for accelerated IoT adoption.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.